Table 1. Biochemical changes in rat hepatic function and oxidant status.
| CON | CCl4 | ESM | |
|---|---|---|---|
| AST (Karmen) | 56.12 ± 2.34a | 207.79 ± 25.0b | 111.68 ± 17.94c |
| ALT (Karmen) | 8.09 ± 0.93a | 38.40 ± 7.81b | 18.98 ± 4.63c |
| Albumin (g/dL) | 4.70 ± 0.21 | 4.84 ± 0.21 | 4.45 ± 0.11 |
| Total protein (g/dL) | 6.95 ± 0.17 | 7.12 ± 0.37 | 6.69 ± 0.14 |
| TBARS (μM) | 3.92 ± 0.29a | 5.11 ± 0.46b | 3.97 ± 0.31a |
| Liver TBARS (μmol/g liver) | 0.46 ± 0.02a | 0.74 ± 0.05b | 0.60 ± 0.03c |
| Hyaluronic acid (ng/ml) | 45.28 ± 6.96a | 77.11 ± 13.14b | 60.30 ± 13.21ab |
| Timp1 (ng/ml) | 3.74 ± 0.23a | 5.76 ± 0.31b | 4.81 ± 0.32c |
| PIIINP (ng/ml) | 0.53 ± 0.10a | 0.91 ± 0.11b | 0.78 ± 0.10ab |
| ELF score | 5.59 ± 0.20a | 6.69 ± 0.24b | 6.15 ± 0.24ab |
CON, control rats; CCl4, rats administered CCl4; ESM, rats given CCl4 and ESM (20 g kg−1); AST, aspartate aminotransferase; ALT, alanine aminotransferase; TBARS, thiobarbituric acid reactive substances; TIMP1, tissue metallopeptidase inhibitor 1; PIIINP, amino-terminal propeptide of type III procollagen, ELF, enhanced liver fibrosis. Data are expressed as mean ± SE in each group (n = 6). Data with different letters (a,b,c) in the same column are significantly different at P < 0.05 by Dunnett's test.